Cargando…

Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Enzalutamide, apalutamide, and darolutamide have all been approved by Food and Drug Administration to treat high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) since 2018 based on interim results of several phase III clinical trials. Final analyses of long-term overa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulati, Yelin, Fan, Yu, Yu, Wei, Zhang, Qian, He, Zhisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555656/ https://www.ncbi.nlm.nih.gov/pubmed/34722276 http://dx.doi.org/10.3389/fonc.2021.733202

Ejemplares similares

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-Analysis
por: Fan, Yu, et al.
Publicado: (2022)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression
por: Gao, Lin, et al.
Publicado: (2022)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
por: Trapika, I Gusti Md Gde Surya C., et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
por: Chung, Doo Yong, et al.
Publicado: (2021)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
por: Zhao, Shankun, et al.
Publicado: (2023)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
por: Zhang, Xianlu, et al.
Publicado: (2023)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
por: Mitsui, Yozo, et al.
Publicado: (2023)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer
por: Jan, Yu Jen, et al.
Publicado: (2019)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqrnarah01t8j576h1t37lu6gk